{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T20:12:21Z","timestamp":1785528741605,"version":"3.56.0"},"reference-count":16,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Arthritis and Rheumatism"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.semarthrit.2024.152602","type":"journal-article","created":{"date-parts":[[2024,12,4]],"date-time":"2024-12-04T07:33:07Z","timestamp":1733297587000},"page":"152602","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Prioritising domains of glucocorticoid therapy to measure in trials: Results from a modified delphi exercise from the OMERACT glucocorticoid impact working group"],"prefix":"10.1016","volume":"71","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2975-176X","authenticated-orcid":false,"given":"Joanna","family":"Tieu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan TL","family":"Cheah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suellen","family":"Lyne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Yip","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nilasha","family":"Ghosh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela","family":"Richards","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin","family":"Christensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel J","family":"Black","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna C","family":"Robson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah L","family":"Mackie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine L","family":"Hill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1197-7864","authenticated-orcid":false,"given":"Susan M","family":"Goodman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.semarthrit.2024.152602_bib0001","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1136\/ard.2008.100008","article-title":"Adverse events of low- to medium-dose oral glucocorticoids in inflammatory diseases: a meta-analysis","volume":"68","author":"Hoes","year":"2009","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"10.1016\/j.semarthrit.2024.152602_bib0002","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.3899\/jrheum.161083","article-title":"A patient-reported outcome measure for effect of glucocorticoid therapy in adults with inflammatory diseases is needed: report from the OMERACT 2016 special interest group","volume":"44","author":"Black","year":"2017","journal-title":"J Rheumatol"},{"issue":"9","key":"10.1016\/j.semarthrit.2024.152602_bib0003","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.3899\/jrheum.181082","article-title":"Toward a core domain set for glucocorticoid impact in inflammatory rheumatic diseases: the OMERACT 2018 glucocorticoid impact working group","volume":"46","author":"Cheah","year":"2019","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2024.152602_bib0004","unstructured":"Beaton D M.L., Grosskleg S., Shea B., Tugwell P. (editors). The OMERACT Handbook 2017. 2017; Available from: https:\/\/omeract.org\/handbook\/."},{"issue":"5","key":"10.1016\/j.semarthrit.2024.152602_bib0005","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1016\/j.semarthrit.2020.06.019","article-title":"The patient's perspective of the adverse effects of glucocorticoid use: a systematic review of quantitative and qualitative studies. From an OMERACT working group","volume":"50","author":"Cheah","year":"2020","journal-title":"Semin Arthritis Rheum"},{"issue":"4","key":"10.1016\/j.semarthrit.2024.152602_bib0006","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1007\/s00296-017-3855-6","article-title":"Patient perceptions of glucocorticoids in anti-neutrophil cytoplasmic antibody-associated vasculitis","volume":"38","author":"Robson","year":"2018","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.semarthrit.2024.152602_bib0007","doi-asserted-by":"crossref","first-page":"189","DOI":"10.2147\/OARRR.S213964","article-title":"A qualitative study of patient perspectives related to glucocorticoid therapy in polymyalgia rheumatica and giant cell arteritis","volume":"11","author":"Hoon","year":"2019","journal-title":"Open Access Rheumatol"},{"issue":"6","key":"10.1016\/j.semarthrit.2024.152602_bib0008","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1097\/RHU.0000000000001313","article-title":"The patients' perspective of important glucocorticoid effects: a nominal group study among patients with systemic lupus erythematosus and myositis","volume":"27","author":"Mirza","year":"2021","journal-title":"JCR J Clin Rheumatol"},{"issue":"4","key":"10.1016\/j.semarthrit.2024.152602_bib0009","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1002\/acr2.11234","article-title":"Perspectives of glucocorticoid use in patients with rheumatoid arthritis","volume":"3","author":"Venter","year":"2021","journal-title":"ACR Open Rheumatol"},{"issue":"8","key":"10.1016\/j.semarthrit.2024.152602_bib0010","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1097\/RHU.0000000000000585","article-title":"A survey of glucocorticoid adverse effects and benefits in rheumatic diseases: the patient perspective","volume":"23","author":"Black","year":"2017","journal-title":"J Clin Rheumatol"},{"key":"10.1016\/j.semarthrit.2024.152602_bib0011","doi-asserted-by":"crossref","DOI":"10.1016\/j.semarthrit.2021.06.010","article-title":"Improving benefit-harm assessment of glucocorticoid therapy incorporating the patient perspective: The OMERACT glucocorticoid core domain set","author":"Tieu","year":"2021","journal-title":"Semin Arthritis Rheum"},{"issue":"8","key":"10.1016\/j.semarthrit.2024.152602_bib0012","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.3899\/jrheum.181096","article-title":"OMERACT Filter 2.1: elaboration of the conceptual framework for outcome measurement in health intervention studies","volume":"46","author":"Boers","year":"2019","journal-title":"J Rheumatol"},{"issue":"8","key":"10.1016\/j.semarthrit.2024.152602_bib0013","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.3899\/jrheum.181097","article-title":"Core domain set selection according to OMERACT Filter 2.1: the OMERACT methodology","volume":"46","author":"Maxwell","year":"2019","journal-title":"J Rheumatol"},{"issue":"5","key":"10.1016\/j.semarthrit.2024.152602_bib0014","doi-asserted-by":"crossref","first-page":"994","DOI":"10.3899\/jrheum.131309","article-title":"Updating the OMERACT filter: core areas as a basis for defining core outcome sets","volume":"41","author":"Kirwan","year":"2014","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2024.152602_bib0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.semarthrit.2023.152338","article-title":"Consensus of the definitions of the OMERACT glucocorticoid impact core domain set for people with rheumatic and musculoskeletal diseases","volume":"64","author":"Lyne","year":"2024","journal-title":"Semin Arthritis Rheum"},{"issue":"8","key":"10.1016\/j.semarthrit.2024.152602_bib0016","doi-asserted-by":"crossref","first-page":"981","DOI":"10.3899\/jrheum.181194","article-title":"The OMERACT-OARSI core domain set for measurement in clinical trials of hip and\/or knee osteoarthritis","volume":"46","author":"Smith","year":"2019","journal-title":"J Rheumatol"}],"container-title":["Seminars in Arthritis and Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017224002427?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017224002427?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,4]],"date-time":"2025-03-04T14:51:38Z","timestamp":1741099898000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049017224002427"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":16,"alternative-id":["S0049017224002427"],"URL":"https:\/\/doi.org\/10.1016\/j.semarthrit.2024.152602","relation":{},"ISSN":["0049-0172"],"issn-type":[{"value":"0049-0172","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prioritising domains of glucocorticoid therapy to measure in trials: Results from a modified delphi exercise from the OMERACT glucocorticoid impact working group","name":"articletitle","label":"Article Title"},{"value":"Seminars in Arthritis and Rheumatism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semarthrit.2024.152602","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"152602"}}